Eikonoklastes completed a series A financing round in the second quarter of 2021. The company was founded to rapidly advance breakthrough technologies, starting with a novel fusion protein for the treatment of triple-negative breast cancer. Eikonoklastes has engineered molecules that attack three key components of the tumor microenvironment by activating the body's natural immune system without harming normal cells, according to the company.

Financial details of the agreement were not disclosed.

Insilico Med, 4B Tech partner on neurodegenerative drug discovery
Insilico Medicine is collaborating with 4B Technologies to develop small-molecule therapies for amyotrophic lateral sclerosis and other major neurological...

Next-generation gene therapy points to base editing
Base editing has emerged as a new player in the gene therapy arena, with rapid advances in technology and evidence of proof of concept in rare genetic...